Irbesartan CAS 138402-11-6 Maʻemaʻe >99.0% (HPLC) API Factory Antihypertensive
Mea Manufacturer Supply, High Purity, Commercial Production
| Inoa Kimia | ʻO Irbesartan |
| Nā huaʻōlelo like | BMS-186295;SR-47436;Aprovel;Avapro;2-Butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en- 4-hoʻokahi;2-Butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one |
| Helu CAS | 138402-11-6 |
| Kūlana Kūʻai | Ma ka waihona, hoʻonui ʻia a hiki i nā tona |
| ʻĀpana Molekala | C25H28N6O |
| Kaumaha Molecular | 428.54 |
| ʻO ka mānoanoa | 1.30±0.10 g/cm3 |
| Solubility i ka wai | ʻAʻole hiki ke hoʻonā i ka wai |
| Brand | Kemika Ruifu |
| 'ikamu | Nā kikoʻī |
| ʻano ʻano | Keʻokeʻo a i ʻole ka pauka kristal keʻokeʻo. |
| Identification Infrared Absorption | Kūlike ka spectrum IR me ka spectrum i loaʻa me Irbesartan RS |
| ʻIke 2 | ʻO ka manawa paʻa o ka piko nui i ka chromatogram o ka assay e pili ana me Irbesartan RS |
| Maʻemaʻe / Kaʻina Hanana | >99.5% (HPLC) |
| Wai | <0.50% |
| Nā Metala Kaumaha | <0.002% |
| Koena ma ka Ignition | <0.10% |
| Na mea pili | (Na HPLC) |
| USP haumia A | <0.20% |
| Kekahi mea haumia ʻike ʻole ʻia | <0.10% |
| Huina paumaele | <0.50% |
| Organic Volatile Impurities | Hoʻokō i nā koi o USP |
| ʻO Azide koena | <10ppm |
| Nā mea hoʻoheheʻe koena | (Na GC) |
| Ethanol | <5000ppm |
| Toluene | <890ppm |
| Dichloromethane | <3000ppm |
| N,N-Dimethylformamide | <880ppm |
| T-Butyl Methyl Etera | <5000ppm |
| Hoʻāʻo | 98.0~102.0% (helu ʻia ma ke kumu anhydrous) |
| Kūlana hoʻāʻo | ʻOihana Kūlana;USP Kūlana |
| Hoʻohana | API;ʻO ka lāʻau antihypertensive;No ka mālama ʻana i ka hypertension |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO Irbesartan (CAS: C) kahi antagonist receptor angiotensin II i hoʻohana nui ʻia no ka mālama ʻana i ka hypertension.Ua hoʻomohala ʻia ʻo Irbesartan e Sanofi Research (i kēia manawa he ʻāpana o Sanofi-Aventis).Kūʻai pū ʻia e Sanofi-Aventis a me Bristol-Myers Squibb ma lalo o nā inoa kālepa ʻo Aprovel, Karvea, a me Avapro.Hoʻohana ʻia ʻo Irbesartan e mālama i ke koko kiʻekiʻe.Ua hoʻokuʻu ʻia ʻo Avapro ma Kelemānia, UK a me US no ka hypertension.E like me nā antagonist receptor angiotensin II āpau, hōʻike ʻia ʻo irbesartan no ka mālama ʻana i ka hypertension.Hiki i ka Irbesartan ke hoʻopaneʻe i ka holomua o ka nephropathy maʻi a hōʻike ʻia no ka hōʻemi ʻana i ka holomua o ka maʻi renal i nā mea maʻi me ka maʻi diabetes type 2, hypertension a me microalbuminuria (> 30 mg / 24 mau hola) a i ʻole proteinuria.Hiki i ka Irbesartan ke hōʻemi i ka hoʻoponopono hou ʻana o ka myocardium, no laila e hōʻemi i ka nui o ka make o nā mea maʻi me ka hypertension, ʻo ia ka lāʻau lapaʻau maikaʻi loa no ka mālama ʻana i ka hypertension a me ka maʻi cardiovascular.
